| Pathophysiology, treatment, and animal and cellular models of human ischemic stroke TM Woodruff, J Thundyil, SC Tang, CG Sobey, SM Taylor, TV Arumugam Molecular neurodegeneration 6, 1-19, 2011 | 800 | 2011 |
| The Concise Guide to PHARMACOLOGY 2019/20: G protein‐coupled receptors SPH Alexander, A Christopoulos, AP Davenport, E Kelly, A Mathie, ... British journal of pharmacology 176, S21-S141, 2019 | 791 | 2019 |
| Quantitative analysis of cellular inflammation after traumatic spinal cord injury: evidence for a multiphasic inflammatory response in the acute to chronic environment KD Beck, HX Nguyen, MD Galvan, DL Salazar, TM Woodruff, ... Brain 133 (2), 433-447, 2010 | 691 | 2010 |
| Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice R Gordon, EA Albornoz, DC Christie, MR Langley, V Kumar, S Mantovani, ... Science translational medicine 10 (465), eaah4066, 2018 | 662 | 2018 |
| T helper 1 immunity requires complement-driven NLRP3 inflammasome activity in CD4+ T cells G Arbore, EE West, R Spolski, AAB Robertson, A Klos, C Rheinheimer, ... Science 352 (6292), aad1210, 2016 | 515 | 2016 |
| The Concise Guide to PHARMACOLOGY 2021/22: G protein‐coupled receptors SPH Alexander, A Christopoulos, AP Davenport, E Kelly, A Mathie, ... British journal of pharmacology 178, S27-S156, 2021 | 494 | 2021 |
| The role of the complement system in ischemia-reperfusion injury TV Arumugam, IA Shiels, TM Woodruff, DN Granger, SM Taylor Shock 21 (5), 401-409, 2004 | 466 | 2004 |
| Toll-like receptors in ischemia-reperfusion injury TV Arumugam, E Okun, SC Tang, J Thundyil, SM Taylor, TM Woodruff Shock 32 (1), 4-16, 2009 | 414 | 2009 |
| Inhibiting the C5–C5a receptor axis TM Woodruff, KS Nandakumar, F Tedesco Molecular immunology 48 (14), 1631-1642, 2011 | 356 | 2011 |
| The concise guide to pharmacology 2017/18: overview SPH Alexander, E Kelly, NV Marrion, JA Peters, E Faccenda, SD Harding, ... British journal of pharmacology 174, S1-S16, 2017 | 314 | 2017 |
| Is the complement activation product C3a a proinflammatory molecule? Re-evaluating the evidence and the myth LG Coulthard, TM Woodruff The Journal of Immunology 194 (8), 3542-3548, 2015 | 308 | 2015 |
| Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer’s disease MI Fonseca, RR Ager, SH Chu, O Yazan, SD Sanderson, FM LaFerla, ... The Journal of Immunology 183 (2), 1375-1383, 2009 | 290 | 2009 |
| Neutrophils—a key component of ischemia-reperfusion injury ZV Schofield, TM Woodruff, R Halai, MCL Wu, MA Cooper Shock 40 (6), 463-470, 2013 | 276 | 2013 |
| C5L2: a controversial receptor of complement anaphylatoxin, C5a R Li, LG Coulthard, MCL Wu, SM Taylor, TM Woodruff The FASEB Journal 27 (3), 855-864, 2013 | 249 | 2013 |
| Eph/Ephrin signaling in injury and inflammation MG Coulthard, M Morgan, TM Woodruff, TV Arumugam, SM Taylor, ... The American journal of pathology 181 (5), 1493-1503, 2012 | 238 | 2012 |
| Complement component 5a (c5a) HD Manthey, TM Woodruff, SM Taylor, PN Monk The international journal of biochemistry & cell biology 41 (11), 2114-2117, 2009 | 231 | 2009 |
| Complement mediators in ischemia–reperfusion injury TV Arumugam, T Magnus, TM Woodruff, LM Proctor, IA Shiels, SM Taylor Clinica Chimica Acta 374 (1-2), 33-45, 2006 | 199 | 2006 |
| The role of the complement system and the activation fragment C5a in the central nervous system TM Woodruff, RR Ager, AJ Tenner, PG Noakes, SM Taylor Neuromolecular medicine 12, 179-192, 2010 | 196 | 2010 |
| A potent human C5a receptor antagonist protects against disease pathology in a rat model of inflammatory bowel disease TM Woodruff, TV Arumugam, IA Shiels, RC Reid, DP Fairlie, SM Taylor The Journal of Immunology 171 (10), 5514-5520, 2003 | 196 | 2003 |
| Neuroprotection in stroke by complement inhibition and immunoglobulin therapy TV Arumugam, TM Woodruff, JD Lathia, PK Selvaraj, MP Mattson, ... Neuroscience 158 (3), 1074-1089, 2009 | 192 | 2009 |
John D LeeUniversity of QueenslandVerified email at uq.edu.au
